Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Combining conventional therapy with immunotherapy: A risky business?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  • A Coosemans
  • A Vankerckhoven
  • T Baert
  • L Boon
  • H Ruts
  • M Riva
  • S Blagden
  • M Delforge
  • N Concin
  • M R Mirza
  • J A Ledermann
  • A du Bois
  • I Vergote
Vis graf over relationer

Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.

OriginalsprogEngelsk
TidsskriftEuropean journal of cancer (Oxford, England : 1990)
Vol/bind113
Sider (fra-til)41-44
Antal sider4
ISSN0959-8049
DOI
StatusUdgivet - maj 2019

Bibliografisk note

Copyright © 2019 Elsevier Ltd. All rights reserved.

ID: 59075179